DAVENPORT & Co LLC Takes Position in Natera, Inc.

The investment firm acquired over 14,000 shares of the medical research company's stock in Q4 2025.

Mar. 28, 2026 at 8:07am

Got story updates? Submit your updates here. ›

DAVENPORT & Co LLC, a financial services firm, acquired a new position in shares of Natera, Inc. (NASDAQ:NTRA) during the fourth quarter of 2025. The fund purchased 14,032 shares of the medical research company's stock, valued at approximately $3.2 million.

Why it matters

Natera is a leading provider of cell-free DNA testing for reproductive health, oncology, and organ transplantation. The company's innovative genetic testing technologies have made it an attractive investment for institutional investors like DAVENPORT & Co LLC, which manages over $20 billion in client assets.

The details

According to a disclosure with the Securities and Exchange Commission, DAVENPORT & Co LLC added the Natera shares to its portfolio in the fourth quarter of 2025. The investment firm's position in Natera represents a new stake, as it did not previously hold shares of the medical research company.

  • DAVENPORT & Co LLC acquired the Natera shares in the fourth quarter of 2025.
  • The disclosure was filed with the SEC on March 28, 2026.

The players

DAVENPORT & Co LLC

A financial services firm that manages over $20 billion in client assets and has acquired a new position in Natera, Inc.

Natera, Inc.

A medical research company that provides innovative cell-free DNA testing solutions for reproductive health, oncology, and organ transplantation.

Got photos? Submit your photos here. ›

The takeaway

The acquisition of Natera shares by DAVENPORT & Co LLC underscores the growing investor interest in the company's cutting-edge genetic testing technologies, which have applications across multiple healthcare sectors.